阿尔茨海默病中的活动:新兴见解和治疗影响
Keith Vossel1, Emily L Johnson2, Benjamin Cretin3
1Department of Neurology, University of California, Los Angeles, CA, USA.
The Lancet. Neurology
|January 25, 2026
概括
活动在阿尔茨海默氏症中很常见,可以加剧认知能力下降. 早期发现和治疗发作可能有助于控制阿尔茨海默病的进展.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 老年病的医生 老年病的医生
背景情况:
- 阿尔茨海默病 (AD) 经常与有关,估计有60%的患者经历发作或亚临床型活动.
- 在认知健康的个体中,发作也会增加痴呆症的风险,这表明双向关系.
研究的目的:
- 探索活动和阿尔茨海默病进展之间的联系.
- 研究抗发作药物的潜力,以改善患有的阿尔茨海默病患者的认知结果.
- 强调早期检测和治疗阿尔茨海默氏症活动的重要性.
主要方法:
- 关于和阿尔茨海默病的当前文献的综述.
- 对研究抗发作药物的认知益处的研究分析.
- 讨论在阿兹海默病患者中检测活动的诊断挑战和进展.
主要成果:
- 活动,包括亚临床排放,可以加速阿尔茨海默病的认知衰退.
- 抗粉胺疗法可能会增加发作风险,需要仔细管理.
- 新出现的证据支持阿尔茨海默病的"性亚型".
结论:
- 活动是阿尔茨海默病的重要,可修改的风险因素.
- 早期识别和针对性治疗活动在所有AD阶段至关重要.
- 警和神经生理监测对于治疗阿尔茨海默病患者的来说至关重要.
更多相关视频
04:22Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles
Published on: May 20, 2024
06:28High-Quality Seizure-Like Activity from Acute Brain Slices Using a Complementary Metal-Oxide-Semiconductor High-Density Microelectrode Array System
Published on: September 27, 2024
相关概念视频
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
